Provider: NIHR Journals Library
Content:text/plain; charset="UTF-8"
TY  - JOUR
LB  - 1.
AU  - Rivellese, F
AU  - Surace, AEA
AU  - Goldmann, K
AU  - Sciacca, E
AU  - Çubuk, C
AU  - Giorli, G
TI  - Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
J2  - Nat Med
PY  - 2022
VL  - 28
SP  - 1256
EP  - 1268
UR  - https://doi.org/10.1038/s41591-022-01789-0
ER  - 
TY  - JOUR
LB  - 2.
AU  - Scott, DL
AU  - Symmons, DP
AU  - Coulton, BL
AU  - Popert, AJ
TI  - Long-term outcome of treating rheumatoid arthritis: results after 20 years
J2  - Lancet
PY  - 1987
VL  - 1
SP  - 1108
EP  - 1111
UR  - https://doi.org/10.1016/S0140-6736(87)91672-2
ER  - 
TY  - JOUR
LB  - 3.
AU  - Aletaha, D
AU  - Smolen, JS
TI  - Diagnosis and management of rheumatoid arthritis: a review
J2  - JAMA
PY  - 2018
VL  - 320
SP  - 1360
EP  - 1372
UR  - https://doi.org/10.1001/jama.2018.13103
ER  - 
TY  - JOUR
LB  - 4.
AU  - Humby, F
AU  - Bombardieri, M
AU  - Manzo, A
AU  - Kelly, S
AU  - Blades, MC
AU  - Kirkham, B
TI  - Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium
J2  - PLOS Med
PY  - 2009
VL  - 6
SP  - e1
UR  - https://doi.org/10.1371/journal.pmed.0060001
ER  - 
TY  - JOUR
LB  - 5.
AU  - Harre, U
AU  - Georgess, D
AU  - Bang, H
AU  - Bozec, A
AU  - Axmann, R
AU  - Ossipova, E
TI  - Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin
J2  - J Clin Invest
PY  - 2012
VL  - 122
SP  - 1791
EP  - 1802
UR  - https://doi.org/10.1172/JCI60975
ER  - 
TY  - JOUR
LB  - 6.
AU  - Edwards, JC
AU  - Szczepanski, L
AU  - Szechinski, J
AU  - Filipowicz-Sosnowska, A
AU  - Emery, P
AU  - Close, DR
TI  - Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
J2  - N Engl J Med
PY  - 2004
VL  - 350
SP  - 2572
EP  - 2581
UR  - https://doi.org/10.1056/NEJMoa032534
ER  - 
TY  - JOUR
LB  - 7.
AU  - Cohen, SB
AU  - Emery, P
AU  - Greenwald, MW
AU  - Dougados, M
AU  - Furie, RA
AU  - Genovese, MC
TI  - Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
J2  - Arthritis Rheum
PY  - 2006
VL  - 54
SP  - 2793
EP  - 2806
UR  - https://doi.org/10.1002/art.22025
ER  - 
TY  - JOUR
LB  - 8.
AU  - Emery, P
AU  - Fleischmann, R
AU  - Filipowicz-Sosnowska, A
AU  - Schechtman, J
AU  - Szczepanski, L
AU  - Kavanaugh, A
TI  - The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial
J2  - Arthritis Rheum
PY  - 2006
VL  - 54
SP  - 1390
EP  - 1400
UR  - https://doi.org/10.1002/art.21778
ER  - 
TY  - JOUR
LB  - 9.
AU  - Emery, P
AU  - Deodhar, A
AU  - Rigby, WF
AU  - Isaacs, JD
AU  - Combe, B
AU  - Racewicz, AJ
TI  - Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE))
J2  - Ann Rheum Dis
PY  - 2010
VL  - 69
SP  - 1629
EP  - 1635
UR  - https://doi.org/10.1136/ard.2009.119933
ER  - 
TY  - JOUR
LB  - 10.
AU  - Cohen, SB
AU  - Keystone, E
AU  - Genovese, MC
AU  - Emery, P
AU  - Peterfy, C
AU  - Tak, PP
TI  - Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
J2  - Ann Rheum Dis
PY  - 2010
VL  - 69
SP  - 1158
EP  - 1161
UR  - https://doi.org/10.1136/ard.2009.119222
ER  - 
TY  - JOUR
LB  - 11.
AU  - Mease, PJ
AU  - Cohen, S
AU  - Gaylis, NB
AU  - Chubick, A
AU  - Kaell, AT
AU  - Greenwald, M
TI  - Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial
J2  - J Rheumatol
PY  - 2010
VL  - 37
SP  - 917
EP  - 927
UR  - https://doi.org/10.3899/jrheum.090442
ER  - 
TY  - JOUR
LB  - 12.
AU  - Rubbert-Roth, A
AU  - Tak, PP
AU  - Zerbini, C
AU  - Tremblay, JL
AU  - Carreño, L
AU  - Armstrong, G
TI  - Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
J2  - Rheumatology
PY  - 2010
VL  - 49
SP  - 1683
EP  - 1693
UR  - https://doi.org/10.1093/rheumatology/keq116
ER  - 
TY  - JOUR
LB  - 13.
AU  - Tak, PP
AU  - Rigby, WF
AU  - Rubbert-Roth, A
AU  - Peterfy, CG
AU  - van Vollenhoven, RF
AU  - Stohl, W
TI  - Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
J2  - Ann Rheum Dis
PY  - 2011
VL  - 70
SP  - 39
EP  - 46
UR  - https://doi.org/10.1136/ard.2010.137703
ER  - 
TY  - JOUR
LB  - 14.
AU  - Breedveld, F
AU  - Agarwal, S
AU  - Yin, M
AU  - Ren, S
AU  - Li, NF
AU  - Shaw, TM
TI  - Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response
J2  - J Clin Pharmacol
PY  - 2007
VL  - 47
SP  - 1119
EP  - 1128
UR  - https://doi.org/ 10.1177/0091270007305297
ER  - 
TY  - JOUR
LB  - 15.
AU  - Teng, YKO
AU  - Levarht, EWN
AU  - Hashemi, M
AU  - Bajema, IM
AU  - Toes, REM
AU  - Huizinga, TWJ
AU  - van Laar, JM
TI  - Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment
J2  - Arthritis Rheum
PY  - 2007
VL  - 56
SP  - 3909
EP  - 3918
UR  - https://doi.org/10.1002/art.22967
ER  - 
TY  - JOUR
LB  - 16.
AU  - Vos, K
AU  - Thurlings, RM
AU  - Wijbrandts, CA
AU  - van Schaardenburg, D
AU  - Gerlag, DM
AU  - Tak, PP
TI  - Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis
J2  - Arthritis Rheum
PY  - 2007
VL  - 56
SP  - 772
EP  - 778
UR  - https://doi.org/10.1002/art.22400
ER  - 
TY  - JOUR
LB  - 17.
AU  - Thurlings, RM
AU  - Vos, K
AU  - Wijbrandts, CA
AU  - Zwinderman, AH
AU  - Gerlag, DM
AU  - Tak, PP
TI  - Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
J2  - Ann Rheum Dis
PY  - 2008
VL  - 67
SP  - 917
EP  - 925
UR  - https://doi.org/10.1136/ard.2007.080960
ER  - 
TY  - JOUR
LB  - 18.
AU  - Kavanaugh, A
AU  - Rosengren, S
AU  - Lee, SJ
AU  - Hammaker, D
AU  - Firestein, GS
AU  - Kalunian, K
TI  - Assessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results
J2  - Ann Rheum Dis
PY  - 2008
VL  - 67
SP  - 402
EP  - 408
UR  - https://doi.org/10.1136/ard.2007.074229
ER  - 
TY  - JOUR
LB  - 19.
AU  - Teng, YKO
AU  - Levarht, EWN
AU  - Toes, REM
AU  - Huizinga, TWJ
AU  - van Laar, JM
TI  - Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation
J2  - Ann Rheum Dis
PY  - 2009
VL  - 68
SP  - 1011
EP  - 1016
UR  - https://doi.org/10.1136/ard.2008.092791
ER  - 
TY  - JOUR
LB  - 20.
AU  - Kormelink, TG
AU  - Tekstra, J
AU  - Thurlings, RM
AU  - Boumans, MH
AU  - Vos, K
AU  - Tak, PP
TI  - Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity
J2  - Ann Rheum Dis
PY  - 2010
VL  - 69
SP  - 2137
EP  - 2144
UR  - https://doi.org/10.1136/ard.2009.126441
ER  - 
TY  - JOUR
LB  - 21.
AU  - Rosengren, S
AU  - Wei, N
AU  - Kalunian, KC
AU  - Kavanaugh, A
AU  - Boyle, DL
TI  - CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis
J2  - Rheumatology
PY  - 2011
VL  - 50
SP  - 603
EP  - 610
UR  - https://doi.org/10.1093/rheumatology/keq337
ER  - 
TY  - JOUR
LB  - 22.
AU  - Hogan, VE
AU  - Holweg, CT
AU  - Choy, DF
AU  - Kummerfeld, SK
AU  - Hackney, JA
AU  - Teng, YK
TI  - Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab
J2  - Ann Rheum Dis
PY  - 2012
VL  - 71
SP  - 1888
EP  - 1894
UR  - https://doi.org/10.1136/annrheumdis-2011-201115
ER  - 
TY  - JOUR
LB  - 23.
AU  - Teng, YK
AU  - Wheater, G
AU  - Hogan, VE
AU  - Stocks, P
AU  - Levarht, EW
AU  - Huizinga, TW
TI  - Induction of long-term B-cell depletion in refractory rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity
J2  - Arthritis Res Ther
PY  - 2012
VL  - 14
SP  - R57
UR  - https://doi.org/10.1186/ar3770
ER  - 
TY  - JOUR
LB  - 24.
AU  - Humby, F
AU  - Lewis, M
AU  - Ramamoorthi, N
AU  - Hackney, JA
AU  - Barnes, MR
AU  - Bombardieri, M
TI  - Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
J2  - Ann Rheum Dis
PY  - 2019
VL  - 78
SP  - 761
EP  - 772
UR  - https://doi.org/10.1136/annrheumdis-2018-214539
ER  - 
TY  - JOUR
LB  - 25.
AU  - Kearsley-Fleet, L
AU  - Davies, R
AU  - De Cock, D
AU  - Watson, KD
AU  - Lunt, M
AU  - Buch, MH
TI  - Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
J2  - Ann Rheum Dis
PY  - 2018
VL  - 77
SP  - 1405
EP  - 1412
UR  - https://doi.org/10.1136/annrheumdis-2018-213378
ER  - 
TY  - ELEC
LB  - 26.
AU  - World Medical Association
TI  - WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects
UR  - https://wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
M1  - 27 April 2021
ER  - 
TY  - ELEC
LB  - 27.
AU  - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
TI  - ICH Guidelines
UR  - https://ich.org/page/ich-guidelines
M1  - 27 April 2021
ER  - 
TY  - JOUR
LB  - 28.
AU  - Aletaha, D
AU  - Neogi, T
AU  - Silman, A
AU  - Funovits, J
AU  - Felson, D
AU  - Bingham, C
TI  - 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
J2  - Arthritis Rheum
PY  - 2010
VL  - 62
SP  - 2569
EP  - 2581
UR  - https://doi.org/10.1002/art.27584
ER  - 
TY  - GEN
LB  - 29.
AU  - National Institute for Health and Care Excellence (NICE)
TI  - Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a TNF Inhibitor
CY  - London
PB  - NICE
PY  - 2010
ER  - 
TY  - JOUR
LB  - 30.
AU  - Kelly, S
AU  - Humby, F
AU  - Filer, A
AU  - Ng, N
AU  - Di Cicco, M
AU  - Hands, RE
TI  - Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 611
EP  - 617
UR  - https://doi.org/10.1136/annrheumdis-2013-204603
ER  - 
TY  - JOUR
LB  - 31.
AU  - Bugatti, S
AU  - Manzo, A
AU  - Vitolo, B
AU  - Benaglio, F
AU  - Binda, E
AU  - Scarabelli, M
TI  - High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease
J2  - Rheumatology
PY  - 2014
VL  - 53
SP  - 1886
EP  - 1895
UR  - https://doi.org/10.1093/rheumatology/keu163
ER  - 
TY  - JOUR
LB  - 32.
AU  - Kraan, MC
AU  - Haringman, JJ
AU  - Ahern, MJ
AU  - Breedveld, FC
AU  - Smith, MD
AU  - Tak, PP
TI  - Quantification of the cell infiltrate in synovial tissue by digital image analysis
J2  - Rheumatology
PY  - 2000
VL  - 39
SP  - 43
EP  - 49
UR  - https://doi.org/10.1093/rheumatology/39.1.43
ER  - 
TY  - JOUR
LB  - 33.
AU  - Baeten, D
AU  - Demetter, P
AU  - Cuvelier, C
AU  - Van Den Bosch, F
AU  - Kruithof, E
AU  - Van Damme, N
TI  - Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity
J2  - Ann Rheum Dis
PY  - 2000
VL  - 59
SP  - 945
EP  - 953
UR  - https://doi.org/10.1136/ard.59.12.945
ER  - 
TY  - JOUR
LB  - 34.
AU  - FANTOM Consortium and the RIKEN PMI and CLST (DGT)
AU  - Forrest, AR
AU  - Kawaji, H
AU  - Rehli, M
TI  - A promoter-level mammalian expression atlas
J2  - Nature
PY  - 2014
VL  - 507
SP  - 462
EP  - 470
UR  - https://doi.org/10.1038/nature13182
ER  - 
TY  - JOUR
LB  - 35.
AU  - Rivellese, F
AU  - Humby, F
AU  - Bugatti, S
AU  - Fossati-Jimack, L
AU  - Rizvi, H
AU  - Lucchesi, D
TI  - B cell synovitis and clinical phenotypes in rheumatoid arthritis: relationship to disease stages and drug exposure
PY  - 2020
VL  - 72
SP  - 714
EP  - 725
UR  - https://doi.org/10.1002/art.41184
ER  - 
TY  - JOUR
LB  - 36.
AU  - Krenn, V
AU  - Morawietz, L
AU  - Burmester, GR
AU  - Kinne, RW
AU  - Mueller-Ladner, U
AU  - Muller, B
AU  - Haupl, T
TI  - Synovitis score: discrimination between chronic low-grade and high-grade synovitis
J2  - Histopathology
PY  - 2006
VL  - 49
SP  - 358
EP  - 364
UR  - https://doi.org/10.1111/j.1365-2559.2006.02508.x
ER  - 
TY  - JOUR
LB  - 37.
AU  - Patro, R
AU  - Duggal, G
AU  - Love, MI
AU  - Irizarry, RA
AU  - Kingsford, C
TI  - Salmon provides fast and bias-aware quantification of transcript expression
J2  - Nat Methods
PY  - 2017
VL  - 14
SP  - 417
EP  - 419
UR  - https://doi.org/10.1038/nmeth.4197
ER  - 
TY  - JOUR
LB  - 38.
AU  - Love, MI
AU  - Huber, W
AU  - Anders, S
TI  - Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
J2  - Genome Biol
PY  - 2014
VL  - 15
SP  - 550
UR  - https://doi.org/10.1186/s13059-014-0550-8
ER  - 
TY  - JOUR
LB  - 39.
AU  - Law, CW
AU  - Chen, Y
AU  - Shi, W
AU  - Smyth, GK
TI  - voom: precision weights unlock linear model analysis tools for RNA-seq read counts
J2  - Genome Biol
PY  - 2014
VL  - 15
SP  - R29
UR  - https://doi.org/10.1186/gb-2014-15-2-r29
ER  - 
TY  - JOUR
LB  - 40.
AU  - Lewis, MJ
AU  - Barnes, MR
AU  - Blighe, K
AU  - Goldmann, K
AU  - Rana, S
AU  - Hackney, JA
TI  - Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes
J2  - Cell Rep
PY  - 2019
VL  - 28
SP  - 2455
EP  - 70.e5
UR  - https://doi.org/10.1016/j.celrep.2019.07.091
ER  - 
TY  - JOUR
LB  - 41.
AU  - Aletaha, D
AU  - Nell, VP
AU  - Stamm, T
AU  - Uffmann, M
AU  - Pflugbeil, S
AU  - Machold, K
AU  - Smolen, JS
TI  - Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
J2  - Arthritis Res Ther
PY  - 2005
VL  - 7
SP  - R796
EP  - R806
UR  - https://doi.org/10.1186/ar1740
ER  - 
TY  - JOUR
LB  - 42.
AU  - Emery, P
AU  - Gottenberg, JE
AU  - Rubbert-Roth, A
AU  - Sarzi-Puttini, P
AU  - Choquette, D
AU  - Taboada, VM
TI  - Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
J2  - Ann Rheum Dis
PY  - 2015
VL  - 74
SP  - 979
EP  - 984
UR  - https://doi.org/10.1136/annrheumdis-2013-203993
ER  - 
TY  - JOUR
LB  - 43.
AU  - Orr, C
AU  - Vieira-Sousa, E
AU  - Boyle, DL
AU  - Buch, MH
AU  - Buckley, CD
AU  - Cañete, JD
TI  - Synovial tissue research: a state-of-the-art review
J2  - Nat Rev Rheumatol
PY  - 2017
VL  - 13
SP  - 630
UR  - https://doi.org/10.1038/nrrheum.2017.161
ER  - 
TY  - JOUR
LB  - 44.
AU  - Jilani, I
AU  - O’Brien, S
AU  - Manshuri, T
AU  - Thomas, DA
AU  - Thomazy, VA
AU  - Imam, M
TI  - Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
J2  - Blood
PY  - 2003
VL  - 102
SP  - 3514
EP  - 3520
UR  - https://doi.org/10.1182/blood-2003-01-0055
ER  - 
TY  - JOUR
LB  - 45.
AU  - Ducreux, J
AU  - Durez, P
AU  - Galant, C
AU  - Nzeusseu Toukap, A
AU  - Van den Eynde, B
AU  - Houssiau, FA
AU  - Lauwerys, BR
TI  - Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium
PY  - 2014
VL  - 66
SP  - 15
EP  - 23
UR  - https://doi.org/10.1002/art.38202
ER  - 
TY  - JOUR
LB  - 46.
AU  - Bresnihan, B
AU  - Pontifex, E
AU  - Thurlings, RM
AU  - Vinkenoog, M
AU  - El-Gabalawy, H
AU  - Fearon, U
TI  - Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers
J2  - J Rheumatol
PY  - 2009
VL  - 36
SP  - 1800
EP  - 1802
UR  - https://doi.org/10.3899/jrheum.090348
ER  - 
TY  - JOUR
LB  - 47.
AU  - Wijbrandts, CA
AU  - Vergunst, CE
AU  - Haringman, JJ
AU  - Gerlag, DM
AU  - Smeets, TJ
AU  - Tak, PP
TI  - Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker
J2  - Arthritis Rheum
PY  - 2007
VL  - 56
SP  - 3869
EP  - 3871
UR  - https://doi.org/10.1002/art.22964
ER  - 
TY  - JOUR
LB  - 48.
AU  - Kane, D
AU  - Veale, DJ
AU  - FitzGerald, O
AU  - Reece, R
TI  - Survey of arthroscopy performed by rheumatologists
J2  - Rheumatology
PY  - 2002
VL  - 41
SP  - 210
EP  - 215
UR  - https://doi.org/10.1093/rheumatology/41.2.210
ER  - 
TY  - JOUR
LB  - 49.
AU  - Beckers, RK
AU  - Selinger, CI
AU  - Vilain, R
AU  - Madore, J
AU  - Wilmott, JS
AU  - Harvey, K
TI  - Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
J2  - Histopathology
PY  - 2016
VL  - 69
SP  - 25
EP  - 34
UR  - https://doi.org/10.1111/his.12904
ER  - 
TY  - JOUR
LB  - 50.
AU  - Smolen, JS
AU  - Aletaha, D
AU  - Redlich, K
TI  - The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
J2  - Nat Rev Rheumatol
PY  - 2012
VL  - 8
SP  - 235
EP  - 243
UR  - https://doi.org/10.1038/nrrheum.2012.23
ER  - 
TY  - JOUR
LB  - 51.
AU  - Ferté, C
AU  - André, F
AU  - Soria, JC
TI  - Molecular circuits of solid tumors: prognostic and predictive tools for bedside use
J2  - Nat Rev Clin Oncol
PY  - 2010
VL  - 7
SP  - 367
EP  - 380
UR  - https://doi.org/10.1038/nrclinonc.2010.84
ER  - 
TY  - JOUR
LB  - 52.
AU  - van der Heijde, D
TI  - How to read radiographs according to the Sharp/van der Heijde method
J2  - J Rheumatol
PY  - 2000
VL  - 27
SP  - 261
EP  - 263
ER  -